Traxion Sab De Cv Ord Shs GRPOF

RE:Aphria buying Tetra is pure speculation...

[sunny3999]

Aphria's 10 mn shares in TBP Annual report excerpt: INVESTMENT IN TETRA BIO-PHARMA INC. On December 6, 2016, Aphria purchased 5,000,000 common shares of Tetra Bio-Pharma Inc. (“TBP”), a company engaged in pain management research, at a price of $0.20 per share for an aggregate purchase price of $1,000,000, pursuant to a private placement. As part of the transaction, Aphria received 5,000,000 warrants, each for conversion into one common share, at a price of $0.26 per warrant for a period of three years. The warrants are subject to an accelerated expiry if TBP’s shares trade above $0.45 for 30 consecutive trading days at which time the warrants will become subject to a 30-day expiry period if not exercised. The Company subsequently exercised the warrants at a cost of $1,300,000.

LeafRider wrote: The whole Aphria, Shoppers, Tetra relationship is interesting, but unless Tetra announces that we've partnered with Shopper's Drug Mart for our OTC line, which we haven't released yet, and IMO it's definitely not Shoppers based on what I know. It's unlikely just because Shopper's has sponsored the research chair at St. Thomas University and Tetra with UNB. Both completely unrelated and drawing a conclusion that everyone is holding hands on R & D is pure speculation.

The other aspect is that Aphria may own 9% of the outstanding shares of Tetra and this relationship will be a good one. Yes, they could decide to sell their shares at any point and that would damage Tetra in a major way. They could also look to purchae more shares which would give a pretty good boost to Tetra's share price. So I'm positive the relationship there is rock solid seeing how we have Aphria's CFO on our board. For some maybe they buy Aphria with a sense that they will see the benefits of Tetra should PPP001 fully come to light. Lots of "IFs" though In my opinion.

The buy itself, if it was to happen I'd suggest Aphria takes a run at Tetra well in advance of PPP001 becoming approved by the FDA / Health Canada. The crazy thing is is the Aphria's CFO will be on the board and be likely to know information regarding the successful phase 3 clinical trials. If everything comes out really positive on the data and results side of things. Aphria would be smart to get on the buyout side of things quickly because I could see Tetra becoming a $300 million company almost over night. Investors should be looking at AXIM and INSY as good examples of what US exposure does to R&D bio pharma companies. If we line up beside these two companies Tetra is NOT that far behind, eventhought we'd need to be $3 share = AXIM and $8=INSY to be on par with their evaluations. Lots of upside here. Lots of people use GW Pharma as a company reference, but both of AXIM and INSY are valid as well.

Reference Link:
https://www.cbc.ca/news/canada/new-brunswick/marijuana-pot-research-chair-unb-stu-new-brunswick-health-pharmaceutical-1.4240450